Dr. Bhatia webinar on the Glymphatic System
The CSF Accumulation of GBCA’s: The Significance of the Glymphatic System
As part of Guerbet’s commitment to research and development they regularly partner with leading researchers and industry associations to create educational webinars that address key findings related to diagnostic imaging.
In The CSF Accumulation of GBCA’s: The Significance of the Glymphatic System, Aashim Bhatia, MD, MS, a pediatric neuroradiologist with extensive research experience, discusses the role and function of the recently discovered glymphatic system.
The recent discovery and exploration of the glymphatic system and the impact on the body is exciting, and it may lead to innovative ways to deliver targeted therapeutics. The glymphatic system is a previously unrecognized waste elimination pathway in the brain—analogous to the lymphatic system in the rest of the body.
There has been growing awareness in regard to gadolinium (Gd) deposits found in the brains of patients who have received multiple doses of contrast. Looking at this system may help radiologists better understand the process of reducing these deposits.
It is currently believed that the glymphatic system has trouble eliminating Gd deposits in the brain. Selecting the most stable gadolinium-based contrast agent (GBCA) helps minimize the risk of Gd retention. In this webinar, Dr. Bhatia details recent research about Gd deposits found in patients who have received GBCAs, and describes how to determine the stability of GBCAs and select an agent that is least likely to be associated with Gd deposition.
In December of 2017, the Food and Drug Administration released a safety announcement regarding (GBCAs), in which it stated the “...FDA is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs.”
As one of the company’s offering a GBCA solution for patients, Guerbet has sponsored Dr Bhatia’s research and developed this webinar in conjunction with the American Society of Neuroradiology (ASNR) annual conference in May of 2021.
About Dr. Bhatia
Dr. Aashim Bhatia is a Pediatric Neuroradiologist who is currently focusing his research on imaging biomarkers in pediatric brain tumors, and more specifically in determining tumor progression and pseudo-progression using advanced imaging. Dr. Bhatia completed his fellowship at the Children’s Hospital of Philadelphia in 2015, and later returned as the Director of Academic Affairs and Assistant Professor in Radiology at the Children’s Hospital of Pittsburgh of UPMC.